Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03381014
Other study ID # speckle echo in cardiomyopathy
Secondary ID
Status Not yet recruiting
Phase N/A
First received December 12, 2017
Last updated December 17, 2017
Start date January 1, 2018
Est. completion date August 1, 2019

Study information

Verified date December 2017
Source Assiut University
Contact Mostafa M Morsy, MD
Phone +201096955959
Email Mostafa_corono@yahoo.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Early detection of cardiomyopathy in patients receiving Anthracycline chemotherapy and determine if speckle tracking echo and Troponin gene will add benefit for early detection of cardiomyopathy.

Improve economic impact of oncologic patients from whom high sensitive troponin negative and normal speckle tracking patients can be safely excluded from long-term cardiac monitoring programs.

To correlate between the molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy


Description:

Anthracycline chemotherapy has saved the lives of many cancer victims during the 50 years after their discovery.These patients are prone to higher risk of cardiovascular death than the risk of tumor recurrence, particularly in childhood cancer survivors in whom the cardiac mortality rate is seven fold higher.

Cardiac toxicity remains an important side effect of anticancer therapies, leading to increased mortality due to mainly heart failure, but also arrhythmias, hypertension, thromboembolism.

The time from early development of cardiac dysfunction to the modification or end of chemotherapy and beginning of heart failure therapy, is an important determinant of the extent of recovery.

The Cardiotoxicity of anthracyclines may be acute, early or late. A recent study involving 2625 patients (mean follow-up 5 years); showed a 9% overall incidence of Cardiotoxicity after anthracycline treatment, 98% of cases occurred within the first year and were asymptomatic.

Cardiotoxicity has been defined using various classifications. Recent guidelines suggest that Cancer therapeutics-related cardiac dysfunction (CTRCD) is defined as a decrease in the LVEF (by echocardiography) of >10 percentage points to a value below the lower limit of normal.

Echocardiography should be repeated before every next administration of anthracycline, after 3, 6, and 12 months from the end of therapy with anthracycline but...Not all patients treated with chemotherapy require such frequently repeated LVEF monitoring as suggested by the guidelines because of the negative impact on patient management and cost-effectiveness ratio for the national health system.

Speckle-tracking echocardiography is a noninvasive ultrasound imaging technique that allows for early an objective and quantitative evaluation of global and regional myocardial function.

New elevation of serum troponin detected with high sensitivity Troponin assays in patients receiving anthracyclines also predicts subsequent LV dysfunction.

Ryanodine receptors (RyRs) are a class of intracellular calcium channels in various forms of excitable tissues like muscles and neurons.

In heart failure the RyR2 channels become abnormally active or "leaky" and are unable to remain closed during diastole. This leads to an increase in spontaneous Ca+2 spark frequency and dysregulated Ca+2 handling within the cardiomyocyte, resulting in decreased systolic contraction and irregular contractile activity.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date August 1, 2019
Est. primary completion date January 1, 2019
Accepts healthy volunteers No
Gender All
Age group 30 Years to 50 Years
Eligibility Inclusion Criteria:

- all Newly diagnosed cancer patients with who will receive Anthracycline based regimen chemotherapy

Exclusion Criteria:

- Insufficient ultrasound image quality, defined as more than three LV segments being suboptimally visualized by conventional echocardiography.

- Valvular heart disease

- Hypertensive heart disease

- Cardiomyopathy

- Chronic renal failure

- Chronic obstructive air way disease (COPD)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chemotherapy, Cancer, Anthracyclines
follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (2)

Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. Revie — View Citation

Henning RJ, Harbison RD. Cardio-oncology: cardiovascular complications of cancer therapy. Future Cardiol. 2017 Jul;13(4):379-396. doi: 10.2217/fca-2016-0081. Epub 2017 Jun 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary early detection of cardiomyopathy using speckle tracking echo to early diagnosis of cardiomyopathy about one year
Primary identify patients whose at risk to develop cardiomyopathy Using the high sensitive troponin with quantitative measurements as biomarker. about one year
Secondary molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy quantitative correlation between the troponin genes and ryanodine receptor in early cardiomyopathy same time frame ... about one year
See also
  Status Clinical Trial Phase
Recruiting NCT06376604 - Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies N/A
Completed NCT03753542 - Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy N/A
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Completed NCT04207359 - Effects of Creatine Supplementation in Breast Cancer Survivors N/A
Active, not recruiting NCT04489173 - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer Phase 2
Completed NCT04173195 - Comfort Talk (CT) During Outpatient Chemotherapy N/A
Recruiting NCT06041477 - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Phase 3
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Recruiting NCT03275194 - HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy Phase 2
Recruiting NCT04808466 - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Completed NCT05131490 - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients N/A
Completed NCT04118322 - The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy N/A
Recruiting NCT06043999 - Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients N/A
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Not yet recruiting NCT04845490 - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT04989985 - S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT05424692 - Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer N/A
Recruiting NCT05992337 - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A